Corona Remedies logo

Corona Remedies

Listed

IPO Timeline

Issue open date

8 Dec 2025

Issue close date

10 Dec 2025

UPI mandate deadline

10 Dec 2025

Allotment finalization

11 Dec 2025

Refund initiation

12 Dec 2025

Share credit

12 Dec 2025

Listing date

15 Dec 2025

Mandate end date

25 Dec 2025

Lock-in end date for anchor investors (50%)

10 Jan 2026

Lock-in end date for anchor investors (remaining)

11 Mar 2026

Grey Market Premium Trend

₹342.5
Current GMP
₹1,405
Est. Listing Price
32.3%
Est. Listing Gain
₹1008 - ₹1062
Price Band

GMP History

DateGMP (₹)Est. Listing Price (₹)Est. Listing Gain
14 Dec₹343₹1,40532.25%
13 Dec₹343₹1,40532.25%
12 Dec₹295₹1,35727.78%
11 Dec₹330₹1,39231.07%
10 Dec₹291₹1,35327.40%
9 Dec₹295₹1,35727.78%
8 Dec₹270₹1,33225.42%
7 Dec₹262₹1,32424.67%
6 Dec₹290₹1,35227.31%
5 Dec₹305₹1,36728.72%
4 Dec₹365₹1,42734.37%
3 Dec₹365₹1,42734.37%
2 Dec₹307₹1,36928.91%
1 Dec₹0₹1,0620.00%

Key Dates

Open
8 Dec 2025
Close
10 Dec 2025
Listing
15 Dec 2025

Quick Stats

Issue Size:655cr
Lot Size:14 shares

About the Company

Corona Remedies, founded in 2004 and headquartered in Ahmedabad, Gujarat, is a pharmaceutical company engaged in the research, manufacturing, and marketing of healthcare products. The company offers a range of products across multiple therapeutic areas, including women’s healthcare, cardio-diabetes, pain management, urology, and more. With two manufacturing facilities located in Gujarat and Himachal Pradesh, Corona Remedies has established a significant presence in the Indian pharmaceutical market. The company’s growth strategy includes organic expansion and strategic acquisitions, aiming to enhance its product portfolio and market reach. Corona Remedies continues to focus on delivering quality healthcare solutions to meet the evolving needs of patients.

Strengths

  • Consistent revenue growth with a CAGR of approximately 21% over the last three years.
  • Diversified product portfolio across multiple therapeutic areas.
  • Strong distribution network with a presence in urban and semi-urban areas.
  • Leadership positions in specific therapeutic segments, such as women’s healthcare and pain management.
  • EU-GMP and WHO-certified manufacturing facilities ensure high-quality production standards

Risks

  • High working capital intensity with a gross operating cycle exceeding 150 days.
  • Exposure to regulatory risks inherent in the pharmaceutical industry.
  • Dependence on contract manufacturing for certain products.
  • Ongoing capital expenditure projects with associated completion and cost risks.
  • Presence in a competitive and price-controlled domestic pharmaceutical market.

Corona Remedies IPO – Frequently Asked Questions

  • The price band for the Corona Remedies IPO is set at ₹1008 to ₹1062 per share.
  • The Corona Remedies IPO opens on December 8, 2025 and closes on December 10, 2025.
  • The tentative listing date for the Corona Remedies IPO is December 15, 2025.
  • You can apply for the Corona Remedies IPO via your broker or bank using ASBA or UPI. Log in to your trading app (Zerodha, Upstox, Groww, etc.), select IPO section, choose Corona Remedies, enter lot quantity and UPI ID, then approve the mandate.
  • The lot size for the Corona Remedies IPO is 14 shares. Investors must apply for at least one lot (i.e., 14 shares).